Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 15;15(5):1170.
doi: 10.3390/v15051170.

HPV Infection of the Oropharyngeal, Genital and Anal Mucosa and Associated Dysplasia in People Living with HIV

Carmen Hidalgo-Tenorio  1 , Inmaculada Calle-Gómez  2 , Raquel Moya-Megías  2 , Javier Rodríguez-Granges  3 , Mohamed Omar  4 , Javier López Hidalgo  5 , Carmen García-Martínez  2
Affiliations

HPV Infection of the Oropharyngeal, Genital and Anal Mucosa and Associated Dysplasia in People Living with HIV

Carmen Hidalgo-Tenorio et al. Viruses. .

Abstract

Background: The main objectives were to describe the prevalence of HPV, its genotypes and HPV-associated dysplastic lesions in the oropharyngeal mucosa of PLHIV and related factors.

Material and methods: This cross-sectional prospective study consecutively enrolled PLHIV attending our specialist outpatient units. At visit, HIV-related clinical and analytical variables were gathered, and oropharyngeal mucosa exudates were taken to detect HPV and other STIs by polymerase chain reaction. Samples were also taken from the anal canal of all participants and from the genital mucosa of the women for HPV detection/genotyping and cytological study.

Results: The 300 participants had a mean age of 45.1 years; 78.7% were MSM and 21.3% women; 25.3% had a history of AIDS; 99.7% were taking ART; and 27.3% had received an HPV vaccine. HPV infection prevalence in the oropharynx was 13%, with genotype 16 being the most frequent (2.3%), and none had dysplasia. Simultaneous infection with Treponema pallidum (HR: 4.02 (95% CI: 1.06-15.24)) and a history of anal HSIL or SCCA (HR: 21.52 (95% CI: 1.59-291.6)) were risk factors for oropharyngeal HPV infection, whereas ART duration (8.8 vs. 7.4 years) was a protective factor (HR: 0.989 (95% CI: 0.98-0.99)).

Conclusions: The prevalence of HPV infection and dysplasia was low in the oropharyngeal mucosae. A higher exposure to ART was protective against oral HPV infection.

Keywords: MSM; PLHIV; cancer; oropharyngeal HPV; women.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Trickey A., May M.T., Vehreschild J.J., Obel N., Gill M.J., Crane H.M., Boesecke C., Patterson S., Grabar S., Cazanave C., et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356. doi: 10.1016/S2352-3018(17)30066-8. - DOI - PMC - PubMed
    1. Mangal T.D., Meireles M.V., Pascom A.R.P., Coelho R.D.A., Benzaken A.S., Hallett T.B. Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006–2015. BMC Infect. Dis. 2019;19:206. doi: 10.1186/s12879-019-3844-3. - DOI - PMC - PubMed
    1. Getaneh Y., Ning F., He Q., Rashid A., Kassa D., Assefa Y. Survival and Predictors of Mortality among Adults Initiating Highly Active Antiretroviral Therapy in Ethiopia: A Retrospective Cohort Study (2007-2019) Biomed. Res. Int. 2022;2022:5884845. doi: 10.1155/2022/5884845. - DOI - PMC - PubMed
    1. Jespersen N.A., Axelsen F., Dollerup J., Nørgaard M., Larsen C.S. The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era. HIV Med. 2021;22:478–490. doi: 10.1111/hiv.13077. - DOI - PMC - PubMed
    1. Haji M., Lopes V.V., Ge A., Halladay C., Soares C., Shah N.R., Longenecker C.T., Lally M., Bloomfield G.S., Shireman T.I., et al. Two decade trends in cardiovascular disease outcomes and cardiovascular risk factors among US veterans living with HIV. Int. J. Cardiol. Cardiovasc. Risk Prev. 2022;15:200151. doi: 10.1016/j.ijcrp.2022.200151. - DOI - PMC - PubMed